Find clinical trials for Leukemia in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia

Acute Myeloid Leukemia

Lymphoid Leukemia

B-Cell Chronic Lymphocytic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Lymphoma

Myelodysplastic Syndromes

Leukemia trials near Roma, Lazio, ITA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...

Enrolling

Acute Leukemia of Ambiguous Lineage

Mixed Phenotype Acute Leukemia

Drug: Ziftomenib

Drug: Itraconazole

Phase 1, Phase 2

Kura Oncology

Roma, Italy and 55 other locations

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling

Acute Leukemia of Ambiguous Lineage

Mixed Phenotype Acute Leukemia

Drug: revumenib

Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals

Roma, Italy and 56 other locations

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting

Chronic Lymphocytic Leukemia

Drug: Acalabrutinib

Phase 3

AstraZeneca

Roma, Italy and 108 other locations

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias...

Enrolling

Accelerated Phase Chronic Myeloid Leukemia

Acute Lymphocytic Leukemia

Drug: Ponatinib

Phase 1, Phase 2

Incyte

Rome, Italy and 32 other locations

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CAN...

Enrolling

Acute Myeloid Leukemia

Relapse/Recurrence

Drug: High intensity therapies

Drug: Low intensity therapies

Phase 3

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Roma, RM, Italy and 31 other locations

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....

Enrolling

Myeloid Leukemia, Philadelphia Positive

Drug: Asciminib Adult formulation group

Drug: Asciminib Pediatric formulation group

Phase 1, Phase 2

Novartis

Roma, RM, Italy and 38 other locations

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia...

Active, not recruiting

B Cell Precursor Acute Lymphoblastic Leukemia

Drug: Blinatumomab

Phase 1, Phase 2

Amgen

Roma, Italy and 42 other locations

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retr...

Enrolling

Chronic Lymphocytic Leukemia (CLL)

Drug: Venetoclax

Drug: Obinutuzumab

Phase 2

AbbVie

Terni, Italy and 54 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting

Leukemia, Myeloid, Acute

Drug: Azacitidine

Drug: AG-120

Phase 1, Phase 2

Celgene

Roma, Italy and 48 other locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with newly diagnosed Positive Chronic Myelogenous Leukemia...

Active, not recruiting

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Drug: Nilotinib

Drug: Asciminib

Phase 3

Novartis

Roma, RM, Italy and 119 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Leukemia in .css-epvm6{white-space:nowrap;}Roma, Lazio

Related conditions:

Leukemia trials near Roma, Lazio, ITA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Find clinical trials for Leukemia in Roma, Lazio